Replication of Human Endogenous Retroviruses in Modern Humans

人内源性逆转录病毒在现代人类中的复制

基本信息

项目摘要

DESCRIPTION (provided by applicant): The functions of the approximately 98% of the human genome that do not encode human cellular proteins remain to be elucidated. Actively replicating endogenous retroviruses entered the human genome millions of years ago and became a stable part of the inherited genetic material, with retroviral elements presently making up approximately 8% of the modern human genome. These viruses subsequently acquired multiple mutations, leading to the widely-held assumption that they are no longer competent to replicate. However, in studying living patients rather than the standard cell lines, we have recently discovered surprising evidence suggesting that in certain patients with cancer HERV-K (HML-2), an endogenous retrovirus that is a relatively recent entrant into the human genome and has been linked to oncogenesis, might still be capable of replication. Replication and transmission of endogenous retroviruses is difficult to prove using standard techniques, however, as these viruses are already present in the genomes of all human cells. Therefore, we have assembled a diverse and expert group of investigators who will test the hypothesis that modern HERV-K (HML-2) can replicate using cutting-edge and complementary techniques. We will use a newly devised molecular system in which antibiotic resistance serves as a surrogate marker to assess whether we can passage virus from the blood of patients in the laboratory. We will also use high-throughput DNA sequencing and Bioinformatics to find full-length functional virus that is present in cancer patients but is not represented in the current draft of the human genome. An infectious clone that is representative of modern HERV-K (HML-2) will be made by using the information gained from the Bioinformatics studies and/or by cloning a full-length virus from the HERV-K RNA found in the blood of patients. This clone will then be tagged with green fluorescent protein and used to directly study replication. Building on our advances using Nuclear Magnetic Resonance (NMR) to visualize spatially correlated dynamics that direct RNA and protein conformational transitions, we will also develop NMR methods to visualize HERV-K (HML-2) replication in vivo. Proof that endogenous retroviruses can still replicate in modern humans will lead to a paradigm shift in thinking about these viruses, and will suggest a role for them in reshaping individual genomes. In addition, as increased expression of chromosomal endogenous retroviral sequences has been linked to cancer and autoimmunity, these findings will be relevant to understanding the pathogenesis of significant diseases. Finally, if replicating, infectious endogenous human retroviruses capable of causing disease can be found in the blood of given individuals, this information will have important implications for the safety of the blood supply.
描述(由申请人提供):不编码人类细胞蛋白的约98%的人类基因组的功能仍有待阐明。活跃复制的内源性逆转录病毒在数百万年前进入人类基因组,并成为遗传物质的稳定部分,逆转录病毒元件目前占现代人类基因组的约8%。这些病毒随后获得了多个突变,导致人们普遍假设它们不再能够复制。然而,在研究活体患者而不是标准细胞系时,我们最近发现了令人惊讶的证据,表明在某些癌症患者中,HERV-K(HML-2),一种内源性逆转录病毒,是一种相对较新的进入人类基因组并与肿瘤发生有关的病毒,可能仍然能够复制。然而,内源性逆转录病毒的复制和传播很难使用标准技术来证明,因为这些病毒已经存在于所有人类细胞的基因组中。因此,我们组建了一个多元化的专家研究小组,他们将测试现代HERV-K(HML-2)可以使用尖端和互补技术复制的假设。我们将使用一种新设计的分子系统,其中抗生素耐药性作为替代标记,以评估我们是否可以在实验室中从患者血液中传代病毒。我们还将使用高通量DNA测序和生物信息学来寻找存在于癌症患者中但未在当前人类基因组草案中表示的全长功能性病毒。将使用从生物信息学研究中获得的信息和/或通过从患者血液中发现的HERV-K RNA克隆全长病毒,制备代表现代HERV-K(HML-2)的感染性克隆。然后将该克隆用绿色荧光蛋白标记并用于直接研究复制。基于我们使用核磁共振(NMR)可视化指导RNA和蛋白质构象转变的空间相关动力学的进展,我们还将开发NMR方法来可视化HERV-K(HML-2)体内复制。内源性逆转录病毒仍然可以在现代人类中复制的证据将导致对这些病毒的思考范式转变,并将表明它们在重塑个体基因组中的作用。此外,由于染色体内源性逆转录病毒序列的表达增加与癌症和自身免疫有关,这些发现将有助于理解重大疾病的发病机制。最后,如果能够在特定个体的血液中发现能够引起疾病的复制性传染性内源性人类逆转录病毒,则该信息将对血液供应的安全性具有重要意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Michael Markovitz其他文献

David Michael Markovitz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Michael Markovitz', 18)}}的其他基金

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
用于鼻内预防和治疗冠状病毒的分子工程凝集素
  • 批准号:
    10629566
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    8311059
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8318290
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    7762721
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    8130630
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    7938774
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    7835950
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8550159
  • 财政年份:
    2009
  • 资助金额:
    $ 124.02万
  • 项目类别:
CXC Chemokines and HIV Pathogenesis
CXC 趋化因子和 HIV 发病机制
  • 批准号:
    7160544
  • 财政年份:
    2005
  • 资助金额:
    $ 124.02万
  • 项目类别:
CXC Chemokines and HIV Pathogenesis
CXC 趋化因子和 HIV 发病机制
  • 批准号:
    6946547
  • 财政年份:
    2005
  • 资助金额:
    $ 124.02万
  • 项目类别:

相似海外基金

Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 124.02万
  • 项目类别:
B cell development, autoimmunity and immune regulation
B 细胞发育、自身免疫和免疫调节
  • 批准号:
    MR/Y033701/1
  • 财政年份:
    2024
  • 资助金额:
    $ 124.02万
  • 项目类别:
    Research Grant
Applying advanced understanding of CTLA-4 function to optimise therapies for autoimmunity
应用对 CTLA-4 功能的深入理解来优化自身免疫疗法
  • 批准号:
    MR/Y001273/1
  • 财政年份:
    2024
  • 资助金额:
    $ 124.02万
  • 项目类别:
    Research Grant
MUC16 (CA125) mutations promote fibrosis and autoimmunity in systemic sclerosis
MUC16 (CA125) 突变促进系统性硬化症的纤维化和自身免疫
  • 批准号:
    478933
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
    Operating Grants
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
  • 批准号:
    10760885
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
  • 批准号:
    10655219
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
Autoimmunity-Associated B Cells in Lupus Nephritis
狼疮性肾炎中自身免疫相关的 B 细胞
  • 批准号:
    10582053
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
Heparan sulfate as a platform to boost regulatory T cell suppression of autoimmunity
硫酸乙酰肝素作为增强调节性 T 细胞抑制自身免疫的平台
  • 批准号:
    490663
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
    Operating Grants
The interplay of sex hormones and chromosomes dictates pathogenicity in progressive CNS autoimmunity.
性激素和染色体的相互作用决定了进行性中枢神经系统自身免疫的致病性。
  • 批准号:
    488982
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
    Operating Grants
Understanding autoimmunity: Why do B cells sometimes attack our tissues instead of protecting us from infections?
了解自身免疫:为什么 B 细胞有时会攻击我们的组织而不是保护我们免受感染?
  • 批准号:
    2889164
  • 财政年份:
    2023
  • 资助金额:
    $ 124.02万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了